Ameriprise Financial Inc. decreased its position in Dynavax Technologies Co. (NASDAQ:DVAX) by 32.6% in the third quarter, according to its most recent 13F filing with the SEC. The firm owned 597,990 shares of the biopharmaceutical company’s stock after selling 289,282 shares during the period. Ameriprise Financial Inc. owned about 0.99% of Dynavax Technologies worth $12,859,000 at the end of the most recent reporting period.

A number of other institutional investors have also recently bought and sold shares of DVAX. Vanguard Group Inc. boosted its stake in Dynavax Technologies by 14.4% in the 1st quarter. Vanguard Group Inc. now owns 1,825,662 shares of the biopharmaceutical company’s stock worth $10,864,000 after purchasing an additional 230,373 shares during the period. Geode Capital Management LLC boosted its stake in Dynavax Technologies by 6.6% in the 1st quarter. Geode Capital Management LLC now owns 290,958 shares of the biopharmaceutical company’s stock worth $1,731,000 after purchasing an additional 18,012 shares during the period. Bank of America Corp DE boosted its stake in Dynavax Technologies by 2.3% in the 1st quarter. Bank of America Corp DE now owns 20,356 shares of the biopharmaceutical company’s stock worth $121,000 after purchasing an additional 456 shares during the period. Russell Investments Group Ltd. boosted its stake in Dynavax Technologies by 24.0% in the 2nd quarter. Russell Investments Group Ltd. now owns 155,095 shares of the biopharmaceutical company’s stock worth $1,496,000 after purchasing an additional 30,036 shares during the period. Finally, Schwab Charles Investment Management Inc. boosted its stake in Dynavax Technologies by 77.6% in the 2nd quarter. Schwab Charles Investment Management Inc. now owns 181,161 shares of the biopharmaceutical company’s stock worth $1,749,000 after purchasing an additional 79,141 shares during the period. 70.61% of the stock is owned by hedge funds and other institutional investors.

In other Dynavax Technologies news, insider Robert Coffman sold 7,500 shares of the stock in a transaction that occurred on Wednesday, December 13th. The shares were sold at an average price of $18.90, for a total value of $141,750.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. 2.90% of the stock is owned by corporate insiders.

Shares of Dynavax Technologies Co. (NASDAQ:DVAX) opened at $19.25 on Monday. Dynavax Technologies Co. has a 12-month low of $3.70 and a 12-month high of $24.45.

Dynavax Technologies (NASDAQ:DVAX) last released its earnings results on Friday, November 3rd. The biopharmaceutical company reported ($0.38) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.53) by $0.15. Dynavax Technologies had a negative net margin of 41,750.95% and a negative return on equity of 51.46%. The company had revenue of $0.05 million during the quarter, compared to the consensus estimate of $0.28 million. During the same quarter in the prior year, the firm earned ($0.90) EPS. The company’s revenue was down 68.8% compared to the same quarter last year. equities analysts anticipate that Dynavax Technologies Co. will post -1.72 earnings per share for the current fiscal year.

DVAX has been the subject of a number of recent analyst reports. Cowen reaffirmed a “buy” rating and issued a $30.00 price objective on shares of Dynavax Technologies in a research note on Friday, November 3rd. Royal Bank of Canada reaffirmed a “buy” rating and issued a $26.00 price objective on shares of Dynavax Technologies in a research note on Friday, September 1st. BidaskClub lowered shares of Dynavax Technologies from a “buy” rating to a “hold” rating in a research note on Wednesday, December 6th. ValuEngine raised shares of Dynavax Technologies from a “sell” rating to a “hold” rating in a research note on Thursday, September 7th. Finally, Cantor Fitzgerald initiated coverage on shares of Dynavax Technologies in a research note on Friday, September 15th. They issued an “overweight” rating and a $24.00 price objective for the company. One equities research analyst has rated the stock with a sell rating, two have issued a hold rating and five have issued a buy rating to the stock. The stock presently has an average rating of “Buy” and a consensus price target of $25.17.

ILLEGAL ACTIVITY WARNING: This piece of content was published by Watch List News and is the sole property of of Watch List News. If you are viewing this piece of content on another website, it was illegally copied and republished in violation of US and international copyright & trademark laws. The legal version of this piece of content can be viewed at https://www.watchlistnews.com/dynavax-technologies-co-dvax-position-reduced-by-ameriprise-financial-inc/1770670.html.

About Dynavax Technologies

Dynavax Technologies Corporation is a clinical-stage immunotherapy company. The Company is focused on leveraging the body’s innate and adaptive immune responses through toll-like receptor (TLR) stimulation. Its product candidates are being investigated for use in multiple cancer indications, as a vaccine for the prevention of hepatitis B and as a disease modifying therapy for asthma.

Want to see what other hedge funds are holding DVAX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Dynavax Technologies Co. (NASDAQ:DVAX).

Institutional Ownership by Quarter for Dynavax Technologies (NASDAQ:DVAX)

Receive News & Ratings for Dynavax Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dynavax Technologies and related companies with Analyst Ratings Network's FREE daily email newsletter.